Piyush Grover, Matthew Krummenacher, Timothy Loy, Anna K. Nowak, Michaela Lucas
{"title":"Omalizumab for management of hypersensitivity reactions to anticancer drugs","authors":"Piyush Grover, Matthew Krummenacher, Timothy Loy, Anna K. Nowak, Michaela Lucas","doi":"10.1111/imj.16464","DOIUrl":null,"url":null,"abstract":"<p>Hypersensitivity reactions to anticancer drugs include treatment-limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti-immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":"54 8","pages":"1396-1400"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imj.16464","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imj.16464","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Hypersensitivity reactions to anticancer drugs include treatment-limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti-immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.
抗癌药物的过敏反应包括限制治疗的毒性。标准的药物脱敏疗法只能提供暂时的耐受性，因此需要重复使用。我们使用抗免疫球蛋白 E 抗体奥马珠单抗来克服对各种抗癌药物的即刻和延迟超敏反应。在本次研究中，八名患者中有七名成功恢复了所需的抗癌药物治疗方案，而无需进行标准的脱敏治疗。没有观察到奥马珠单抗的安全性问题。
期刊介绍：
The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
